Search
Flunixin
go.drugbank.com/drugs/DB11518ExperimentalVet approvedFlunixin is a non-steroidal anti-inflammatory drug for use in pigs, cattle and horses. It exerts analgesic and antipyretic effects. This drug is often prepared for use in meglumine salt form. … Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian.
Asapiprant
go.drugbank.com/drugs/DB20492InvestigationalAre Not in Respiratory Failure). … Asapiprant is under investigation in clinical trial NCT04705597 (Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That
Alofanib
go.drugbank.com/drugs/DB20918InvestigationalAlofanib is under investigation in clinical trial NCT04071184 (Study of Alofanib in Patients With Metastatic Gastric Cancer). Alofanib has a monoisotopic molecular weight of 413.07 Da. … The usage of the INN stem '-anib' in the name indicates that Alofanib is a angiogenesis inhibitor.
Ceramide NP
go.drugbank.com/drugs/DB14111InvestigationalCeramide NP is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin. … Ceramide 3 consists of a phytosphingosine backbone N-acylated with a saturated fatty acid (stearic acid) [A27233]. It is widely used as a moisturizer in various cosmetic and personal products.
Synonyms: Cer(t18:0/18:1n-9), N-oleoylphytosphingosineMivebresib
go.drugbank.com/drugs/DB21300InvestigationalMivebresib is under investigation in clinical trial NCT04480086 (Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants … The usage of the INN stem '-bresib' in the name indicates that Mivebresib is a inhibitor of the bromodomain and extra-terminal motif (BET) family of bromodomain (BRD) protein, antineoplastic.
PLX51107
go.drugbank.com/drugs/DB17543Investigational[A257246,A257251] PLX51107 is under investigation in clinical trial NCT04022785 (PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome).